H7N9 VLP vaccine: Phase I/II data

Top-line data from an observer-blinded, placebo-controlled, U.S. Phase I/II trial in 610 healthy volunteers ages 18-64 showed that 2 doses of intramuscular H7N9 VLP vaccine given 21 days apart with or...